ArticleMedComm2025
Prevalence, Risk Factors, Lung Function, and Associated Comorbidities of Adult Preserved Ratio Impaired Spirometry: A Meta-Analysis.
Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence of PRISm and COPD and associated factors in a university medical centre spirometry unit: a cross-sectional analysis.BMJ open · 2026Article
- Arterial Stiffness in Pre-COPD/PRISm, and COPD Stages: A Cross-Sectional Assessment of Hemodynamic Determinants.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is demonstrated that preserved ratio impaired spirometry (PRISm) is associated with chronic obstructive pulmonary disease development and mortality. However, comprehensive evidence on its prevalence, risk factors, lung function, and comorbidities is ambiguous. We searched for relevant studies from Medline, Web of Science, Embase, and Scopus up to March 26, 2024, and conducted a meta-analysis based on PRISMA 2020 to merge the results of eligible studies to reveal the prevalence, risk factors, lung function, and associated comorbidities in PRISm population. Thirty-two studies involving 1,196,856 participants were included. The prevalence of PRISm was 11% (95%CI: 10-13%), with decreased forced vital capacity (FVC) (L) (MD: -0.78, 95%CI: -0.90 to -0.66) and FVC% predicted (MD: -24.74, 95%CI: -26.33 to -23.16). Older age, high body mass index, current or ever smoking, and low education were positively associated with PRISm, while cardiovascular and endocrine comorbidities were common in patients with PRISm. The prevalence of PRISm is high in general population, with multiple risk factors, reduced lung function, and increased comorbidities. Therefore, clinicians should raise more concerns regarding this population to benefit them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.